According to the latest research by FMI, Specialty Control Plasma is set to witness a 10.6% growth during the year 2021-2031. The specialty control plasma has gained significant traction by their application in the treatment of a range of conditions such as cardiac insufficiency, immune deficiency, hemorrhages, neurological conditions and infectious diseases. Additionally, specialty control plasma are used by clinical labs for assays to diagnose coagulation disorders such as hemophilia.
The advancement in the process of blood therapeutics and the key application of specialty control plasma in rheumatology, neurology, oncology, immunology, hematology and transplant have proven to be vital in patient care.
What is Driving Demand for Specialty Control Plasma?
The specialty control plasma demand is driven by the rising instances of need of diagnostics for various coagulation disorders. The rising incidence of various autoimmune disorders, such as hemophilia and the growing role of the plasma and its derivative products in the diagnosis as well as treatment of the disorders has significantly acted as a catalyst to the specialty control plasma demand.
In addition, the growing awareness about specialized plasma products and their uptake, especially in the developed economies has added traction to the demand of specialty control plasma. Furthermore, special insurance aid policies by various bodies like the National Hemophilia Foundation, is expected to aid in the development of specialty control plasma.
Which Factors are Likely to Augment Growth of Specialty Control Plasma Adoption?
Factors likely to augment the growth of specialty control plasma are the advancements in the specialized plasma-derived products and the plasma fractionation process. The rising geriatric population around the world and the prevalence of infectious diseases is also likely to act as a propelling factor for the specialty control plasma adoption for treatment and patient care.
Apart from this, the rising reported misdiagnosed conditions such as coagulation disorders is set to push the uptake of specialty control plasma for a significantly accurate diagnosis or detection. The advancements in biomedical technologies and detection assays as well as the growing awareness in terms of detection of immunological disorders is set to supplement the growth of specialty control plasma.
US and Canada Specialty Control Plasma Outlook
The specialty control plasma value is expected to experience a profitable growth in the region of North America over the forecast period. The current stance of this region is dominating globally in terms of development and manufacture of specialty control plasma.
The largest player in US and Canada, Precision Biologics, recently launched CRYOcheck for diagnosis of hemophilia A. Therefore, the growth of specialty control plasma in the region of North America is fueled by the rise in expenditure by various biotechnology companies as well as rising rate of improved healthcare structure.
Europe Demand Outlook for Specialty Control Plasma
The Europe specialty control plasma market is set to become the most lucrative segment over the forecast period owing to the high incidence of chronic diseases and the recognition and visibility of rare diseases as defined by the European Commission.
About 5000 – 8000 rare diseases are prevalent and affect almost 6-8% of the European population. The increasing fund allocation for such rare disorders has led to the advancement of specialty control plasma techniques for diagnosis as well as treatment or management of such disorders.
Who are the Key Manufacturers and Suppliers of Specialty Control Plasma?
The key companies dealing with specialty control plasma are
- Precision BioLogic Incorporated
- Baxter BioScience
- Grifols S.A.
- Shire Plc.
- Kedrion S.p.A.
- China Biologic Products (Shandong Taibang)
- Biotest AG
- Talecris Biotherapeutics
- SK Plasma Co.
- CSL Ltd.
- Octapharma AG
- Cerus Corp.
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
Specialty Control Plasma Market Report Highlights:
- Detailed overview of parent market
- Changing market dynamics in the industry
- In-depth market segmentation
- Historical, current and projected market size in terms of volume and value
- Recent industry trends and developments
- Competitive landscape
- Strategies of key players and products offered
- Potential and niche segments, geographical regions exhibiting promising growth
- A neutral perspective on market performance
- Must-have information for market players to sustain and enhance their market footprint
Note: Although care has been taken to maintain the highest levels of accuracy in FMI’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.
- Factor VIII Concentrate
- Factor IX Concentrate
- Coagulation disorders
- Von Willebrand disease
- Other clotting disorders
- Immunodeficiency diseases
By End User:
- Diagnostic Laboratories
- North America
- Latin America
- South Asia
- Rest of South Asia
- East Asia
- South Korea
- Middle East and Africa
- GCC Countries
- South Africa
Market Research Methodology - Perfected through Years of Diligence
A key factor for our unrivaled market research accuracy is our expert- and data-driven research methodologies. We combine an eclectic mix of experience, analytics, machine learning, and data science to develop research methodologies that result in a multi-dimensional, yet realistic analysis of a market.